Several key questions remain unanswered regarding the use of GLP‐1 RAs in patients with HF and obesity, requiring further investigation across clinical, mechanistic, and implementation domains (Figure 4). The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.